Study of SHR-A1921 or SHR-A2009 for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new drugs, SHR-A1921 and SHR-A2009, for people with advanced non-small cell lung cancer that has progressed after prior treatment with an antibody-drug conjugate. The goal is to see if these drugs can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
- You have already tried a type of targeted therapy called an antibody-drug conjugate (ADC) and it stopped working.
- You are between 18 and 75 years old.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- You do not have untreated brain metastases or other serious lung conditions like ILD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (SHR-A1921 and adebrelimab) for people with advanced non-small cell lung cancer whose cancer has grown after standard first-line treatment. The goal is to see if this new combination can help shrink tumors or slow their growth.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests a new drug called SHR-A1811 in patients with advanced, incurable lung cancer that has a specific genetic change in the HER2 gene. The drug may help slow or stop cancer growth by targeting this genetic change.
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.